Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept for Anemia in Myelodysplastic Syndromes with del(5q)
2021-001538-20Phase 2Active
- Sponsor
- Qol-one
- Start
- Apr 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of luspatercept in myelodysplastic syndrome (MDS), sponsored by Qol-one. Primary endpoint: Red blood cell transfusion independence. Started Apr 2022; status: active.
02
Drugs
luspatercept
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2021-001538-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001538-20.